东宝生物
(300239)
| 流通市值：30.96亿 | | | 总市值：31.17亿 |
| 流通股本：5.90亿 | | | 总股本：5.94亿 |
| 报告期 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 190,525,037.37 | 745,307,726.02 | 532,797,977.19 | 369,055,800.99 |
| 营业收入 | 190,525,037.37 | 745,307,726.02 | 532,797,977.19 | 369,055,800.99 |
| 二、营业总成本 | 168,542,826.28 | 679,496,993.61 | 479,925,097.45 | 327,726,411.88 |
| 营业成本 | 144,255,143.98 | 571,236,707.7 | 402,128,895.05 | 275,176,850.03 |
| 税金及附加 | 2,793,272.19 | 11,319,719.73 | 8,121,413.38 | 5,389,593.69 |
| 销售费用 | 4,877,689.22 | 19,025,129.39 | 13,505,319.55 | 9,435,417.36 |
| 管理费用 | 10,970,426.91 | 51,175,787.99 | 36,123,934.77 | 24,413,751.7 |
| 研发费用 | 5,268,894.44 | 25,481,838.96 | 18,907,749.32 | 12,476,486.44 |
| 财务费用 | 377,399.54 | 1,257,809.84 | 1,137,785.38 | 834,312.66 |
| 其中:利息费用 | 855,955.03 | 4,011,729.68 | 3,151,033.47 | 2,268,836.6 |
| 其中:利息收入 | 644,074.1 | 2,775,997.22 | 1,980,268.15 | 1,343,190.4 |
| 三、其他经营收益 | | | | |
| 加:投资收益 | -650,492.84 | -2,861,860.37 | -2,163,655.2 | -1,566,045.78 |
| 资产处置收益 | 26,172.58 | -93,367.15 | -75,476.56 | -90,612.61 |
| 资产减值损失(新) | -2,381,654.83 | -15,126,490.31 | -4,747,143.37 | -3,128,326.29 |
| 信用减值损失(新) | 580,869.45 | -876,562.79 | 369,080.85 | 336,794.19 |
| 其他收益 | 3,028,983.63 | 12,848,944.23 | 9,123,188.45 | 5,144,013.21 |
| 四、营业利润 | 22,586,089.08 | 59,701,396.02 | 55,378,873.91 | 42,025,211.83 |
| 加:营业外收入 | 522,480 | 3,064,518.06 | 735,566.53 | 413,287.68 |
| 减:营业外支出 | 868.7 | 846,118.92 | 219,346.28 | 37,161.13 |
| 五、利润总额 | 23,107,700.38 | 61,919,795.16 | 55,895,094.16 | 42,401,338.38 |
| 减:所得税费用 | 3,413,627.17 | 7,584,386.18 | 7,447,458.66 | 5,434,215.23 |
| 六、净利润 | 19,694,073.21 | 54,335,408.98 | 48,447,635.5 | 36,967,123.15 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 19,694,073.21 | 54,335,408.98 | 48,447,635.5 | 36,967,123.15 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 19,694,073.21 | 54,337,306.91 | 48,449,538.05 | 36,967,330.23 |
| 少数股东损益 | - | -1,897.93 | -1,902.55 | -207.08 |
| 扣除非经常损益后的净利润 | 17,298,974.15 | 44,161,488.26 | 42,055,914.73 | 33,435,102.1 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.03 | 0.09 | 0.08 | 0.06 |
| (二)稀释每股收益 | 0.03 | 0.09 | 0.08 | 0.06 |
| 九、综合收益总额 | 19,694,073.21 | 54,335,408.98 | 48,447,635.5 | 36,967,123.15 |
| 归属于母公司股东的综合收益总额 | 19,694,073.21 | 54,337,306.91 | 48,449,538.05 | 36,967,330.23 |
| 归属于少数股东的综合收益总额 | - | -1,897.93 | -1,902.55 | -207.08 |
| 公告日期 | 2026-04-24 | 2026-03-30 | 2025-10-29 | 2025-08-29 |
| 审计意见(境内) | | 标准无保留意见 | | |